Compare GE Vernova Inc (GEV) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Vernova Inc vs Smith & Nephew plc — how do they compare? GE Vernova Inc trades at $1,043 (market cap $269.50B), while Smith & Nephew plc trades at $29.67 (market cap $12.54B). The key difference: GE Vernova Inc is far larger — about 21.5× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.65%). Which is the better fit depends on your goals.
| GEV | SNN | |
|---|---|---|
Market Cap | $269.50B | $12.54B |
Sector | Technology | Health |
52-Week High | $1.17K | $38.70 |
52-Week Low | $547.96 | $28.73 |
Enterprise Value | $259.17B | $15.57B |
Dividend Yield | 0.2% | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Vernova (GEV) trades at $1,038.13, up 4.77% with strong bullish momentum. The stock shows robust fundamentals with 23% net income margin and 91% ROE, though valuation ratios appear elevated. Recent Q2 2026 earnings missed expectations, but the company maintains a massive $176 billion backlog and benefits from AI-driven power demand. Technical indicators show bullish moving averages with neutral oscillators, while analyst consensus remains strongly positive with 76% buy ratings.
Outlook remains positive given GEV's strategic positioning in AI infrastructure and energy transition, but premium valuation and execution risks on backlog conversion warrant caution. The stock offers growth exposure to power grid modernization with upside to the $1,270 consensus target, though investors should monitor quarterly execution against high expectations.
Smith & Nephew (SNN) trades at $30.08, down 0.1% with bearish technical signals. The company reported mixed Q2 2026 results with revenue growth below expectations, leading to a reduced full-year outlook. Fundamentals show strong profitability with 10.1% net margin and improving cash flow trends, though recent earnings misses have tempered sentiment.
Outlook remains cautious with analyst consensus at Hold (65% of coverage). Near-term risks include U.S. orthopedics weakness and competitive pressures, offset by robotics innovation and value-based care expansion. The stock offers stable fundamentals but faces execution challenges in key markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
